Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.46 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | LAP3 | P28838 | 2/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.41 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4753936 | 0.98 | CSNK1E (0.48) | CSNK1ESIGMAR1TAAR1AOC3SPPL2A | |
| Hydrochloric Acid SCHEMBL496211 | 0.98 | CSNK1E (0.48) | CSNK1ESIGMAR1TAAR1AOC3SPPL2A | |
| Hydrochloric Acid SCHEMBL4753935 | 0.98 | CSNK1E (0.48) | CSNK1ESIGMAR1TAAR1AOC3SPPL2A | |
| SCHEMBL22626653 | 0.84 | SPPL2A (0.53) | CSNK1ESIGMAR1TAAR1AOC3SPPL2A | |
| SCHEMBL496176 | 0.84 | CSNK1E (0.51) | CSNK1ESIGMAR1TAAR1AOC3SPPL2A | |
| SCHEMBL13118762 | 0.84 | SPPL2A (0.53) | CSNK1ESIGMAR1TAAR1AOC3SPPL2A | |
| Hydrochloric Acid SCHEMBL496241 | 0.83 | CSNK1E (0.50) | CSNK1ESIGMAR1TAAR1AOC3SPPL2A | |
| SCHEMBL496237 | 0.82 | CSNK1E (0.55) | CSNK1ESIGMAR1TAAR1SPPL2AEPHX1 | |
| Hydrochloric Acid SCHEMBL496260 | 0.81 | CSNK1E (0.54) | CSNK1ESIGMAR1TAAR1SPPL2AEPHX1 | |
| Hydrochloric Acid SCHEMBL15062952 | 0.81 | CSNK1E (0.54) | CSNK1ESIGMAR1TAAR1SPPL2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910317-B1 | 1-AMINO LINKED COMPOUNDS | LILLY CO ELI (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-1910317-B1 | 1-AMINO LINKED COMPOUNDS | LILLY CO ELI (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8106090-B2 | Antidiabetic agents; prevent of non-insulin dependent diabetes | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106090-B2 | Antidiabetic agents; prevent of non-insulin dependent diabetes | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106090-B2 | Antidiabetic agents; prevent of non-insulin dependent diabetes | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-20080207735-A1 | 1-Amino Linked Compounds | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080207735-A1 | 1-Amino Linked Compounds | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080207735-A1 | 1-Amino Linked Compounds | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| WO-2007015805-A1 | 1-AMINO LINKED COMPOUNDS | ELI LILLY AND COMPANY (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207735-A1 | 1-Amino Linked Compounds | DPP4, DPP3, DPP9 | CSNK1E 194/4885SIGMAR1 281/4885TAAR1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.